20 November 2025
20 November 2025
Eylea HD’s new RVO indication and a monthly dosing option will notch up the rivalry with Roche’s Vabysmo.
Alkermes will likely proceed with its planned acquisition of Avadel, which experienced an unexpected hitch following Lundbeck’s counteroffer.
Redemplo’s approval in familial chylomicronemia syndrome places the drug in competition with Ionis’ Tryngolza.
The SC formulation facilitates outpatient initiation and decreases administration time to one minute.
The state's attorney general had initiated legal proceedings in November 2023.
The two new sites fall under the Swiss pharma’s $23bn US manufacturing onshoring strategy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
